Daclatasvir (USAN), also known as BMS-790052 and EBP-883 (trade name Daklinza), is NS5A inhibitor and a drug for the treatment of hepatitis C (HCV). It is was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA. Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.
Zong X, Cai J, Chen J, Wang P, Zhou G, Chen B, Li W, Ji M. Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication. Bioorg Med Chem Lett. 2015 Aug 15;25(16):3147-50. doi: 10.1016/j.bmcl.2015.06.006. Epub 2015 Jun 9. PubMed PMID: 26077493.
Moore TO, Paradowski M, Ward SE. An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C-H activation. Org Biomol Chem. 2016 Mar 28;14(12):3307-13. doi: 10.1039/c6ob00340k. PubMed PMID: 26936019.
Pack, Shawn K.; Geng, Peng; Smith, Michael J.; Hamm, Jason. Process for synthesizing peptidomimetics useful for treating hepatitis C. WO 2009020825. (Assignee Bristol-Myers Squibb Company, USA)
Thibeault, Carl; Edwards, Paul J.; Kuhn, Cyrille; Moreau, Benoit; Poirier, Maude; Surprenant, Simon. Preparation of biphenyls end-capped with peptide derivatives as inhibitors of HCV NS5A for the treatment of hepatitis C viral infection. WO 2012048421. (Assignee Boehringer Ingelheim International GmbH, Germany)
Ji, Min; Liu, Fei; Zong, Xi; Wang, Shanchun; Cai, Jin; Feng, Weiwei. Process for preparation of daclatasvir and derivatives thereof. CN 105753944. (Assignee Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Peop. Rep. China; Suzhou Southeast Pharmaceuticals Co., Ltd.)
Rao, Dharmaraj Ramachandra; Malhotra, Geena; Phull, Manjinder Singh; Kanathala, Shashirekha; Gangrade, Manish Gopaldas. Polymorphic forms of Methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof. WO 2016102979. (Assignee Cipla Limited, India; King, Lawrence)
Rao, Dharmaraj Ramachandra; Malhotra, Geena; Phull, Manjinder Singh. Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2- ((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)- 1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof. IN 2014MU04166. (Assignee Cipla Limited, India
Rao, Dharmaraj Ramachandra; Malhotra, Geena; Phull, Manjinder Singh. Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2- ((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)- 1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof. IN 2014MU04166. (Assignee Cipla Limited, India
Kou, Jingping; Lin, Biyue; Cheng, Sanping; Chen, Hui; Wu, Shuming. Method for preparing daclatasvir. CN 106188015. (Assignee Sunshine Lake Pharma Co., Ltd., Peop. Rep. China)
Yan, Qing; Xie, Hai; Chen, Wenrui; Bai, Shunqiang; Zhang, Li. A synthetic method of daclatasvir. CN 106256825. (Assignee Sichuan Tongsheng Biopharmaceutical Co., Ltd., Peop. Rep. China)
